Compare · UNH vs YDES
UNH vs YDES
Side-by-side comparison of UnitedHealth Group Incorporated (UNH) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both UNH and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- UNH is the larger of the two at $386.95B, about 2229.8x YDES ($173.5M).
- Over the past year, UNH is up 51.0% and YDES is down 82.0% - UNH leads by 133.0 points.
- UNH has been more active in the news (13 items in the past 4 weeks vs 3 for YDES).
- UNH has more recent analyst coverage (25 ratings vs 0 for YDES).
- Company
- UnitedHealth Group Incorporated
- YD Bio Limited
- Price
- $426.06+0.66%
- $2.41+1.90%
- Market cap
- $386.95B
- $173.5M
- 1M return
- +4.44%
- -25.85%
- 1Y return
- +51.02%
- -81.96%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 13
- 3
- Recent ratings
- 25
- 0
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
Latest UNH
- UnitedHealth upgraded by Robert W. Baird with a new price target
- UnitedHealth Group Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- UnitedHealth Group Reports Second Quarter 2026 Results
- UnitedHealthcare Launches New Spending Account Benefit, Putting More Choice in the Hands of Consumers
- Director Noseworthy John H was granted 206 shares, increasing direct ownership by 3% to 7,616 units (SEC Form 4)
- Director Montgomery Rice Valerie Md was granted 220 shares, increasing direct ownership by 3% to 7,876 units (SEC Form 4)
- Director Mcnabb Frederick William Iii was granted 250 shares, increasing direct ownership by 2% to 15,462 units (SEC Form 4)
- Director Gottlieb Scott was granted 210 shares, increasing direct ownership by 47% to 659 units (SEC Form 4)
- Director Gil Kristen was granted 206 shares, increasing direct ownership by 9% to 2,617 units (SEC Form 4)
- Director Garcia Paul R was granted 220 shares, increasing direct ownership by 6% to 3,906 units (SEC Form 4)
Latest YDES
- YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
- Director Lu Shao-Ta converted options into 5,749 units of Ordinary Shares, increasing direct ownership by 276% to 7,830 units (SEC Form 4)
- Director Chang Kochi converted options into 5,749 units of Ordinary Shares, increasing direct ownership by 276% to 7,830 units (SEC Form 4)
- SEC Form EFFECT filed by YD Bio Limited
- SEC Form POS AM filed by YD Bio Limited
- YD Bio Limited Reports Full Year 2025 Financial Results
- SEC Form 20-F filed by YD Bio Limited
- Amendment: SEC Form 3 filed by new insider Lu Shao-Ta
- SEC Form 4 filed by Lu Shao-Ta
- SEC Form 4 filed by Chang Kochi